+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastrointestinal Diseases Therapeutics Market - Global Forecast 2026-2032- Product Image
Gastrointestinal Diseases Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Gastrointestinal Diseases Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674215
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gastrointestinal diseases therapeutics market is entering a critical phase where clinical innovation, demographic change, and evolving reimbursement models converge, driving both opportunity and operational complexity for stakeholders. Senior decision-makers seeking to future-proof growth strategies should closely examine how scientific breakthroughs and regulatory dynamics are redefining patient care and commercial models within this space.

Market Snapshot: Gastrointestinal Diseases Therapeutics Market

The global gastrointestinal diseases therapeutics market advanced from USD 43.52 billion in 2025 to USD 45.30 billion in 2026, charting a compound annual growth rate (CAGR) of 4.11% and projecting a value of USD 57.71 billion by 2032. This rise reflects growing prevalence of chronic GI diseases, demand for advanced treatment options, and strong innovation across classes, from biologics to digital platforms.

Scope & Segmentation

This report offers comprehensive segmentation intelligence across multiple dimensions that inform investment and commercialization decisions:

  • Indication Clusters: Acid-Related Disorders (Dyspepsia, Gastroesophageal Reflux Disease, Peptic Ulcer Disease), Infectious Gastroenteritis (Bacterial, Parasitic, and Viral origins), Inflammatory Bowel Disease (Crohn’s Disease, Ulcerative Colitis), and Irritable Bowel Syndrome (Constipation-Predominant, Diarrhea-Predominant, Mixed Type).
  • Therapeutic Classes: Aminosalicylates, Antibiotics (e.g., Ciprofloxacin, Metronidazole, Rifaximin), Antidiarrheals, Antispasmodics, Biologics (Anti-Integrin, Anti-TNF, Interleukin Inhibitors), H2 Receptor Antagonists, Laxatives, Proton Pump Inhibitors.
  • Administration Routes: Oral, Parenteral, Topical—each selected for patient preference, adherence, and formulation investment considerations.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy, shaping commercial and access strategies.
  • Dosage Forms: Injectable solution, oral powder, oral suspension, tablet/capsule, each influencing manufacturing and lifecycle management.
  • End Users: Clinic, home healthcare, and hospital settings—driving delivery logistics and support service requirements.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific, each characterized by unique regulatory, payer, and adoption patterns.
  • Technologies: Biologics, microbiome science, targeted immunotherapies, precision diagnostics, digital health platforms, and telemedicine solutions.

Key Takeaways

  • Strategic alignment of drug development with payer priorities and real-world evidence generation is essential for commercial success in the gastrointestinal therapeutics space.
  • Adoption of innovative diagnostic tools and digital health platforms is enabling earlier diagnosis, improved patient stratification, and decentralized clinical trial execution.
  • Companies that diversify portfolios—combining biologics, microbiome therapeutics, and companion diagnostics—can respond effectively to market shifts and patient needs.
  • Regional market access requires tailored evidence generation and localization strategies to address distinct payer systems and regulatory frameworks.
  • Operational priorities include enhancing supply chain resilience, flexible manufacturing capabilities, and investment in specialty formulations to mitigate risk and support innovation.
  • Cross-functional alignment between R&D, regulatory, access, and commercial teams ensures efficient evidence generation and responsive go-to-market execution.

Tariff Impact on the Gastrointestinal Diseases Therapeutics Market

Recent U.S. trade policy shifts have affected pharmaceutical procurement and pricing strategies by increasing the cost of active ingredients and import components. In response, many stakeholders are restructuring supplier portfolios, accelerating localization of production, and prioritizing strategic alliances to balance cost pressures with innovation investment. Compliance teams face new documentation and customs requirements, whose operational impact is visible across trial logistics and reimbursement negotiations.

Methodology & Data Sources

This analysis synthesizes findings from structured interviews with clinicians, payers, trial experts, and senior pharma executives, supplemented by reviews of regulatory filings, clinical trial registries, peer-reviewed publications, and public company disclosures. Triangulation of primary and secondary evidence, enhanced by expert validation and quality assurance protocols, ensures actionable and reliable guidance for stakeholders.

Why This Report Matters

  • Provides a holistic, segmented view enabling leaders to prioritize investments and optimize resource allocation across diverse therapeutic and regional opportunities.
  • Delivers actionable intelligence on clinical and commercial innovation trajectories, ensuring strategies reflect evolving market access and regulatory realities.
  • Supports risk mitigation and strategic partnerships by detailing supply chain, manufacturing, and pipeline trends relevant to patient outcomes and ROI.

Conclusion

Stakeholders navigating the gastrointestinal therapeutics sector must blend clinical innovation with agile commercialization and robust risk mitigation. Strategic use of segmentation, technology, and cross-functional execution will be key to driving measurable returns and sustainable patient impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gastrointestinal Diseases Therapeutics Market, by Indication
8.1. Acid-Related Disorders
8.1.1. Dyspepsia
8.1.2. Gastroesophageal Reflux Disease
8.1.3. Peptic Ulcer Disease
8.2. Infectious Gastroenteritis
8.2.1. Bacterial Gastroenteritis
8.2.2. Parasitic Infections
8.2.3. Viral Gastroenteritis
8.3. Inflammatory Bowel Disease
8.3.1. Crohn's Disease
8.3.2. Ulcerative Colitis
8.4. Irritable Bowel Syndrome
8.4.1. Constipation-Predominant
8.4.2. Diarrhea-Predominant
8.4.3. Mixed Type
9. Gastrointestinal Diseases Therapeutics Market, by Drug Class
9.1. Aminosalicylates
9.2. Antibiotics
9.2.1. Ciprofloxacin
9.2.2. Metronidazole
9.2.3. Rifaximin
9.3. Antidiarrheals
9.4. Antispasmodics
9.5. Biologics
9.5.1. Anti Integrin Agents
9.5.2. Anti Tumor Necrosis Factor Agents
9.5.3. Interleukin Inhibitors
9.6. H2 Receptor Antagonists
9.7. Laxatives
9.8. Proton Pump Inhibitors
10. Gastrointestinal Diseases Therapeutics Market, by Route Of Administration
10.1. Oral
10.2. Parenteral
10.3. Topical
11. Gastrointestinal Diseases Therapeutics Market, by Dosage Form
11.1. Injectable Solution
11.2. Oral Powder
11.3. Oral Suspension
11.4. Tablet Capsule
12. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Gastrointestinal Diseases Therapeutics Market, by End User
13.1. Clinic
13.2. Home Healthcare
13.3. Hospital
14. Gastrointestinal Diseases Therapeutics Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Gastrointestinal Diseases Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Gastrointestinal Diseases Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Gastrointestinal Diseases Therapeutics Market
18. China Gastrointestinal Diseases Therapeutics Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Abbott Laboratories
19.6. AbbVie Inc.
19.7. Amgen Inc.
19.8. AstraZeneca PLC
19.9. Bausch Health Companies Inc.
19.10. Bayer AG
19.11. Biogen Inc.
19.12. Boehringer Ingelheim International GmbH
19.13. Bristol-Myers Squibb Company
19.14. Cipla Limited
19.15. Dr. Reddy’s Laboratories Ltd.
19.16. Eli Lilly and Company
19.17. F. Hoffmann-La Roche Ltd
19.18. Ferring B.V.
19.19. Gilead Sciences, Inc.
19.20. GSK plc
19.21. Johnson & Johnson
19.22. Merck & Co., Inc.
19.23. Novartis AG
19.24. Novo Nordisk A/S
19.25. Organon & Co.
19.26. Pfizer Inc.
19.27. Sanofi S.A.
19.28. Sun Pharmaceutical Industries Limited
19.29. Takeda Pharmaceutical Company Limited
19.30. Teva Pharmaceutical Industries Ltd.
19.31. UCB SA
19.32. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 195. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 196. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 197. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 198. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 199. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 200. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 201. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 202. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 204. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 221. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 222. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 223. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 224. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 225. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 227. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 228. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 230. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 236. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 239. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 240. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 241. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 243. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 244. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 246. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 247. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 248. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 249. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 250. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 251. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 252. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 254. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 255. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 257. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 260. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 261. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
TABLE 262. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
TABLE 263. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 264. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
TABLE 265. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 266. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 267. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 268. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 269. GCC GASTROINTESTINAL DIS

Companies Mentioned

The key companies profiled in this Gastrointestinal Diseases Therapeutics market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring B.V.
  • Gilead Sciences, Inc.
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 45.3 Billion
Forecasted Market Value ( USD ) by 2032 $ 57.71 Billion
Compound Annual Growth Rate4.1%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Gastrointestinal Drugs Market - Global Forecast 2026-2032 - Product Image

Gastrointestinal Drugs Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Peptide Based Gastrointestinal Disorder Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Peptide Based Gastrointestinal Disorder Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Gastrointestinal Therapeutics Market Report 2025 - Product Image

Gastrointestinal Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Gastrointestinal Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Gastrointestinal Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 110 Pages
  • Global
From
Gastrointestinal Agents Market - Global Forecast 2026-2032 - Product Image

Gastrointestinal Agents Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.